A federal demonstration program will pay for GLP 1 weight loss drugs (Wegovy, Zepbound and their cousins) for adults 65+ starting July 2026, but the underlying statute still bars Medicare from covering obesity drugs.
Starting in July 2026, Medicare will pay for GLP-1 obesity drugs for adults 65 and older for the first time in the program's history, through a federal demonstration program officially scheduled to expire at the end of 2027 (STAT+).
GLP-1s are the class of injectable drugs (Ozempic, Wegovy, Zepbound and their cousins) that have reshaped obesity treatment since the early 2020s. Medicare is statutorily prohibited from paying for them for weight loss alone, a restriction written into the program in 2003 that is still on the books today (STAT+). The specific statutory citation for this coverage exclusion — for example, the relevant provision of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 — is not reproduced in the available source excerpt.
The Trump administration is not asking Congress to change that law. It is routing coverage through a Centers for Medicare & Medicaid Services (CMS) demonstration program called Bridge, which gives the Secretary of Health and Human Services authority to test new payment and delivery models without a statutory change. Bridge is, on paper, a stopgap.
The original design was a three-year program called BALANCE that was supposed to follow Bridge. Under BALANCE, private Medicare Advantage insurers would have voluntarily covered the drugs after the transitional bridge period ended, betting that negotiated prices and patient outcomes would pencil out. The payers declined. STAT+ reports that Medicare Advantage plans balked at the proposed prices and the actuarial risk, and the federal government is extending Bridge instead (STAT+).
That collapse is the part that matters. It is the practical reason a "temporary" program is now slated to run through the end of 2027, and it is the structural reason that ending it later will be hard.
CMS demonstration programs live and die by their enrollments. Once a Medicare beneficiary is on a GLP-1, with a prescription, a prior authorization on file, and a documented clinical response, the political cost of pulling that coverage climbs in proportion to the number of seniors affected. A benefit framed as transitional becomes, by enrollment, a baseline.
The mechanism is not unique. Medicare has used demonstration authority to test the Affordable Care Act's bundled-payment initiatives, which have since informed permanent payment policy. Demonstrations rarely shrink cleanly in the middle of a benefit cycle; they either fade or ratchet upward.
The fiscal exposure is the part the statute did not anticipate. Medicare's actuaries have not published a public cost estimate for Bridge, and the Congressional Budget Office has not scored it. GLP-1 list prices have been publicly reported in the four-figure range per patient per month, and CMS has not disclosed the net prices it has negotiated for the demonstration. If enrollment tracks the patterns private insurers and employer plans already see (high initial uptake, persistent use, modest discontinuation), Bridge becomes a multi-billion-dollar annual line item running outside the normal appropriations process.
The precedent risk is structural. The exclusion of weight-loss drugs from Medicare coverage is a statutory category-level ban, not a procedural oversight. Demonstration authority is meant to test new payment models, not to override category-level coverage bans written by Congress. If Bridge is treated as a precedent, future administrations have a ready template for covering other drug classes that Congress has explicitly excluded, a path that sidesteps the normal legislative fight over what Medicare is for.
What to watch next: the published Bridge participation rules, the first quarterly enrollment report, the negotiated net price, and the administration's first formal decision on whether to extend Bridge past 2027. The administration can also fold Bridge into a successor demonstration, which would preserve enrollment without a single explicit act of permanence. The structural pressure points are visible now, even if the political choice is not.